PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
03-Feb-2023 Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development Businesswire
03-Feb-2023 New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care Businesswire
03-Feb-2023 Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma Businesswire
03-Feb-2023 KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference Businesswire
03-Feb-2023 IMFINZI (DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN APPROVED IN GREAT BRITAIN AS A FIRST-LINE TREATMENT FOR ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER AstraZeneca
03-Feb-2023 Tezspire approved for self-administration in the US with a new pre-filled pen AstraZeneca
03-Feb-2023 CAS and Torx Software collaborate to streamline and accelerate small molecule discovery and design Torx Software
03-Feb-2023 AC Immune to Present at the SVB Securities Global Biopharma Conference AC Immune
03-Feb-2023 OptiBiotix to showcase its progressive microbiome research at Probiota 2023 OptiBiotix
03-Feb-2023 New Phesi analysis reveals almost a fifth of investigator sites in cancer trials have recruited only one patient Phesi Inc
03-Feb-2023 IMFINZI (DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN APPROVED IN GREAT BRITAIN AS A FIRST-LINE TREATMENT FOR ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER AstraZeneca
03-Feb-2023 North America Gastrointestinal Therapeutics Market Research Report 2022 - ResearchAndMarkets.com Businesswire
03-Feb-2023 Re:course AI Secures $4.3m to Reimagine Healthcare Training with AI-Powered Digital Humans Re:course AI
03-Feb-2023 Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma Anaveon
03-Feb-2023 Pharmapack Europe Awards Winners 2023 Pharmapack
03-Feb-2023 BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes(TM) for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients BioCardia
03-Feb-2023 Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market Vetter
03-Feb-2023 The World Health Organisation chooses British air purification company, MedicAir, to tackle ‘invisible threat’ in hospitals MedicAir
03-Feb-2023 Pharma industry urges halt to further rises in record revenue clawbacks ABPI
03-Feb-2023 MHRA Approves RINVOQ®▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease AbbVie